Posted by A PCT patent application on lonafarnib / SBECD formulation was published on 20 May 2021 (WO2021095008, CycloLab, Hungary). By using SBECD, a soluble complex of the drug could be achieved which was evaluated as novel by the selected search authority (European Patent Office) over the HPBCD-based known suspension used in preclinical testing (Hernandez et al., Science Translational Medicine, 11 , eaat3005 (2019)) and other prior art documents.
On November 20, 2020, the U.S. Food and Drug Administration approved non-CD based Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older.
Also, there is a Phase III study in recruitment stage for a non-CD based lonafarnib-ritonavir combination (investigator: Eiger BioPharmaceuticals, USA) to evaluate the efficacy and safety in patients chronically infected with hepatitis delta virus (HDV).